1. Home
  2. AIN vs NVAX Comparison

AIN vs NVAX Comparison

Compare AIN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Albany International Corporation

AIN

Albany International Corporation

HOLD

Current Price

$52.94

Market Cap

1.7B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$7.98

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIN
NVAX
Founded
1895
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
AIN
NVAX
Price
$52.94
$7.98
Analyst Decision
Hold
Hold
Analyst Count
4
9
Target Price
$60.25
$11.33
AVG Volume (30 Days)
242.7K
3.6M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
2.14%
N/A
EPS Growth
N/A
309.76
EPS
N/A
2.58
Revenue
$1,054,132,000.00
$1,123,479,000.00
Revenue This Year
$1.20
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.98
Revenue Growth
7.29
64.69
52 Week Low
$41.15
$5.01
52 Week High
$73.00
$11.85

Technical Indicators

Market Signals
Indicator
AIN
NVAX
Relative Strength Index (RSI) 47.38 36.31
Support Level $51.74 $6.35
Resistance Level $53.88 $8.45
Average True Range (ATR) 1.73 0.53
MACD 0.20 -0.25
Stochastic Oscillator 66.19 12.15

Price Performance

Historical Comparison
AIN
NVAX

About AIN Albany International Corporation

Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: